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ExacerbationAbstract Objectives: To evaluate the role of serum Angiopoietin-2 and C-reactive protein as
blood biomarkers of acute exacerbation of COPD and to assess if they have a relationship with
the severity of COPD and the severity grades of exacerbations.
Background: Recently, Angiopoietin-2 (Ang-2) was identiﬁed as a ligand of the endothelial
receptor tyrosine kinase, Tie-2. Ang-2 is an Angiopoietin-1 antagonist that plays a role in vascular
destabilization and remodeling, which may increase in some diseases. However, serum Ang-2 levels
have not been evaluated in patients with COPD.
In this study, we examined serum Ang-2 concentrations in patients with COPD exacerbations
and in patients with stable COPD.
Methods: This study was conducted on 36 COPD patients in acute exacerbation, 20 patients
with stable COPD and 20 healthy subjects (control group), they were selected from the Shibin-
Elkoom Chest Hospital from February 2013 to October 2013. All subjects were subjected to
detailed clinical history, thorough clinical examination, Modiﬁed British Medical Research
Council (mMRC) questionnaire and the COPD Assessment Test questionnaire (CAT) to assess
symptoms, plain chest-X-ray (postero-anterior and lateral views). Blood sample for the measure-
ment of Angiopoietin-2 and C-reactive protein by ELISA.
Results: Serum concentrations of Ang-2 and CRP were signiﬁcantly higher in patients with acute
exacerbations of COPD than in those with stable COPD or control subjects. Ang-2 was signiﬁcantly
positively correlated with serum CRP levels but negatively correlated with PaO2 in patients with
exacerbations.
838 A.A. Ali et al.Conclusion: Serum levels of Ang-2 and CRP are signiﬁcantly elevated during acute exacerbations
of COPD, as compared with stable COPD.
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Tuberculosis.Introduction
Chronic obstructive pulmonary disease (COPD) is character-
ized by persistent airﬂow limitation, which is progressive and
not fully reversible with an enhanced inﬂammatory response
of the airways and the lung parenchyma to noxious particles
or gases [1]. It is increasingly recognized that in addition to
an inﬂammatory process in the lung itself, systemic inﬂamma-
tion plays an important role in COPD [2].
Recent studies have provided evidence that inﬂammation
exists in a mutually dependent association with angiogenesis
[3].
Angiopoietin-2 (Ang-2) is an important mediator of angio-
genesis and has been implicated in many inﬂammatory dis-
eases. COPD is characterized by systemic inﬂammation,
which is enhanced during exacerbations and may be assessed
by measuring serum C- reactive protein (CRP) [4].
Aim of the study
The aim of this study was to evaluate the role of serum
Angiopoietin-2 and C-reactive protein as blood biomarkers
of acute exacerbation of COPD and to assess if they have a
relationship with the severity of COPD and the severity grades
of exacerbations.
Methods
A written consent was obtained from all subjects prior to
inclusion and the regional ethics committee of the Menouﬁa
University hospital approved the study. The study was con-
ducted in the Shibin-Elkoom Chest Hospital from February
2013 to October 2013.
Study subjects were divided into two groups: Group A;
included 56 patients with COPD diagnosed and classiﬁed
according to GOLD 2013. These patients were classiﬁed into
2 groups:
Group (1): 36 COPD patients in acute exacerbations.
Group (2): 20 stable COPD patients.
COPD patients in acute exacerbations were divided into 3
grades according to the American Thoracic Society/European
Respiratory Society (ATS/ERS): 9 patients in level I (ambula-
tory), 14 patients in level II (hospitalization) and13 patients in
level III (respiratory failure) [5].
Group B included 20 healthy nonsmoker volunteers who
had no symptoms or signs of any chest disease and normal pul-
monary function tests as a control group.
All patients in the present study underwent full history
taking, complete clinical examination, routine laboratory
investigations, chest X-ray (postero-anterior and lateral views).
They also underwent pulmonary function tests. We used2 questionnaires to assess symptoms; the Modiﬁed British
Medical Research Council (mMRC) questionnaire and the
COPD Assessment Test (CAT) [6]. Blood samples were
obtained from all subjects for measurement of Angiopoietin-2
and C-reactive protein by ELISA.
Results
There was a statistically signiﬁcant difference between patients
and controls regarding PaCO2 and a highly statistically signif-
icant difference regarding PaO2, and SaO2. There was a highly
statistically signiﬁcant difference between patients and controls
regarding post bronchodilator FEV1, FEV1/FVC, FEF25–
75%). Also, there was a highly statistically signiﬁcant differ-
ence regarding pre bronchodilator FEV1, serum levels of
Angiopoietin-2 and C-reactive protein between COPD patients
and controls (Table 1).
There was a statistically signiﬁcant difference between
stable COPD patients and patients in acute exacerbation
regarding SaO2% and a highly statistically signiﬁcant differ-
ence between stable COPD patients and patients in acute exac-
erbation regarding PaO2. There was a highly statistically
signiﬁcant difference between stable COPD patients and
patients in acute exacerbation regarding post bronchodilator
FEV1, FEV1/FVC, FEF25–75%. Also, there was a highly sta-
tistically signiﬁcant difference between stable COPD patients
and patients in exacerbation regarding serum levels of
Angiopoietin-2 and C-reactive protein (Table 2).
When we compared COPD patients in different levels of
acute exacerbation, we found that there was a highly statisti-
cally signiﬁcant difference between levels of exacerbation in
COPD patients in exacerbation regarding PaO2 and serum
levels of Angiopoietin-2 and C–reactive protein between
ambulatory and respiratory failure patients and between hos-
pitalized and respiratory failure patients. Also, there was a
highly statistically signiﬁcant difference regarding post bron-
chodilator FEV1 between ambulatory and hospitalized
patients and between ambulatory and respiratory failure
patients and between hospitalized and respiratory failure
patients. (Table 3).
There was a highly statistically signiﬁcant correlation
between serum levels of Angiopoietin-2 and C-reactive protein
regarding PaO2, SaO2%, and post bronchodilator FEV1,
FEV1/FVC, FEF25–75%.
Serum levels of Angiopoietin-2 and CRP were highly signif-
icant negatively correlated with PaO2, and SaO2%, post bron-
chodilator FEV1, FEV1/FVC, and FEF25–75% (Table 4).Discussion
Recent studies have suggested that angiogenesis is another
interesting aspect of COPD [7], it has not been considered to
be part of the mechanism of COPD until recently [8].
Table 1 Statistical comparison between patients and controls regarding arterial blood gas values and pulmonary function test results
and serum levels of Angiopoietin-2 and C-reactive protein.
Parameters COPD patients N= (56) Control N= (20) Test P value
PaO2 (mmHg) 66.49 ± 9.267 97.50 ± 0.51 24.92 P0.001**
pH 7.27 ± 0.667 7.38 ± 0.012 0.759 <0.05
PCO2 (mmHg) 44.07 ± 8.07 39.50 ± 1.05 2.514 P0.05*
SaO2% 88.53 ± 13.10 97.80 ± 0.76 3.148 P0.001**
Pre bronchodilator FEV1 45.64 ± 12.45 92.90 ± 1.84 16.85 P0.001**
Post bronchodilator FEV1% predicted L(X± SD) 48.08 ± 13.50 93.60 ± 1.46 14.97 P0.001**
Post bronchodilator FEV1/FVC (X± SD) 58.69 ± 9.47 100.50 ± 1.39 19.57 P0.001**
Post bronchodilator FEF25–75%L/S (X± SD) 31.58 ± 14.85 92.00 ± 1.45 18.08 P0.001**
Angiopoietin-2 (pg/ml) (X± SD) 430.49 ± 910.87 145.52 ± 75.05 13.915 P0.001**
CRP (mg/dL) (X± SD) 53.50 ± 32.42 4.30 ± 0.923 11.34 P0.001**
* Signiﬁcant.
** Highly signiﬁcant.
Table 2 Statistical comparison between stable COPD patients and patients in exacerbation regarding arterial blood gases and
pulmonary functions test results and serum levels of Angiopoietin-2 and C-reactive protein.
Parameters Stable COPD N= (20) COPD exacerbation N= (36) Test P value
PaO2 (mmHg) 73.14 ± 6.55 62.80 ± 8.51 4.706 P0.001**
pH 7.19 ± 0.91 7.31 ± 0.49 0.667 <0.05
PCO2 (mmHg) 42.55 ± 5.23 44.91 ± 9.24 1.047 <0.05
SaO2% 93.74 ± 1.93 85.63 ± 15.6 2.302 >0.05
FEV1 post (X± SD) 61.65 ± 6.93 40.58 ± 9.87 8.43 P0.001**
FEV1/FVC post (X± SD) 66.1 ± 5.05 54.58 ± 8.86 5.33 P0.001**
FEF25–75% post (X± SD) 47.55 ± 9.52 22.72 ± 8.42 10.09 P0.001**
Angiopoietin-2 (pg/ml) (X± SD) 339.31 ± 630.11 479.45 ± 526.72 5.67 P0.001**
CRP (mg/dL) (X± SD) 27.10 ± 13.77 66.16 ± 30.93 4.38 P0.001**
* Signiﬁcant.
** Highly signiﬁcant.
Biomarkers of acute exacerbations of chronic obstructive pulmonary diseases 839Angiogenesis is an important, well-coordinated process that is
regulated by many angiogenic factors. One of the main partici-
pants in this process is Angiopoietin [9].
In the present study there was a highly statistically signiﬁ-
cant difference between patients and controls regarding
PaO2, and SaO2 (Table 1). And a highly statistically signiﬁ-
cant difference between stable COPD patients and patients
in exacerbation regarding PaO2 (Table 2).
These results were in agreement with Raba (2007) who sta-
ted that with deterioration of pulmonary function and disease
progression, the risk of alveolar hypoxia and consequent
hypoxemia increases [10], which supports our result.
A study done by Faganello et al. (2010) showed that lower
peripheral SaO2 was a risk factor for COPD exacerbation [11].
In the present study there was a highly statistically signiﬁ-
cant difference between patients and controls regarding post
bronchodilator FEV1, FEV1/FVC, FEF25–75%. (Table 1).
These results agreed with Marina et al. (2000) who found
signiﬁcant lower values of FEV1 and FEV1% in smokers with
COPD than in control [12].
In the present study there was a highly statistically signiﬁ-
cant difference between ambulatory and respiratory failure
patients and between hospitalized and respiratory failure
patients regarding PaO2. (Table 3).
These results were in agreement with Francioisi (2006) who
found that oxygen saturation gradually decreased with increas-
ing exacerbation severity [13].In the present study there was a highly statistically signiﬁ-
cant difference regarding post bronchodilator FEV1 between
ambulatory and hospitalized patients and between ambulatory
and respiratory failure patients and between hospitalized and
respiratory failure patients (Table 3).
While there was a statistically signiﬁcant difference between
ambulatory and hospitalized and between ambulatory and res-
piratory failure patients regarding post bronchodilator
FEF25–75 (Table 3).
These results were in agreement with Franciosi (2006) who
assessed the spirometric measurement of FEV1 and FVC as well
as FEV1/FVC, they observed statistically signiﬁcant differences
with exacerbation severity, and between out- and in-patients [13].
In the present study there was a highly statistically sig-
niﬁcant difference between patients and controls and
between stable COPD patients and patients in exacerbation
regarding serum levels of Angiopoietin-2 and CRP (Tables
1 and 2).
These results were matched with Cho et al. (2010) who
showed that serum Ang-2 levels were elevated in patients expe-
riencing acute COPD exacerbations, as compared to patients
with stable COPD. Ang-2 levels decreased when the patients
recovered from their exacerbation [14].
Also, Nikolakopoulou et al. (2014) found that serum Ang-2
levels were signiﬁcantly higher on D1 compared to D7 during
the course of COPD exacerbations which is in accordance with
the previous ﬁndings [15].
Table 3 Statistical comparison between levels of exacerbation in COPD patients in exacerbation regarding arterial blood gases and
pulmonary function test results and serum levels of Angiopoietin-2 and C-reactive protein.
Parameter Level (1)
Ambulatory
N= 9
Level (2)
Hospitalized
N= 14
Level (3)
Respiratory failure
N= 13
ANOVA P value Post hoc
LCD
PaO2 (mmHg) 69.88 ± 10.63 64.71 ± 5.36 55.84 ± 3.21 13.31 >0.001 P1 < 0.05
P2 6 0.001**
P3 6 0.001**
pH 7.38 ± 0.027 7.42 ± 0.045 7.16 ± 0.83 1.023 <0.05 –
PCO2 (mmHg) 41.18 ± 6.27 46.39 ± 9.61 45.89 ± 10.43 0.985 <0.05 –
SaO2% 84.86 ± 21.92 92.61 ± 2.14 78.66 ± 16.61 3.015 <0.05 –
Post bronchodilator FEV1%
predicted L (X± SD)
53.33 ± 5.54 73.14 ± 4.18 35.46 ± 8.98 22.52 >0.001 P1 6 0.001**
P2 6 0.001**
P3 6 0.001**
Post bronchodilator
FEV1/FVC (X± SD)
59.77 ± 6.12 53.64 ± 8.48 52.00 ± 9.88 2.34 <0.05 –
Post bronchodilator
FEF25–75% L/S (X± SD)
28.33 ± 6.30 20.71 ± 7.01 21.00 ± 9.78 Kruskal–Wallis test 6.33 >0.05 P1 6 0.05*
P2 6 0.05*
P3 > 0.05
Angiopoietin-2 (pg/ml) (X± SD) 412.50 ± 466.13 486.87 ± 382.35 517.82 ± 62.55 Kruskal–Wallis test 25.07 >0.001 P1 < 0.05
P2 6 0.001**
P3 6 0.001**
Tamhan test
CRP (mg/dL) (X± SD) 30.66 ± 24.81 78.42 ± 22.10 77.53 ± 24.31 Kruskal–Wallis test 16.08 >0.001 Tamhan test
P1 < 0.05
P2 6 0.001**
P3 6 0.001**
P1 between ambulatory and hospitalized.
P2 between ambulatory and respiratory failure.
P3 between hospitalized and respiratory failure.
* Signiﬁcant.
** Highly signiﬁcant.
840 A.A. Ali et al.Cho et al. (2010) indicated that Ang-2 may be clinically use-
ful as a biomarker of COPD exacerbations. Biomarkers are
useful for assessing the degree of Inﬂammation, monitoring
the inﬂammatory process [14].
Muller (2002) gave evidence that circulating levels of VEGF
and markers of systemic inﬂammation are up-regulated in
patients with acute exacerbated COPD and decrease after
recovery from the exacerbation [16].
In the present study there was a highly statistically signiﬁ-
cant positive correlation between serum levels of
Angiopoietin-2 and C-reactive protein (Table 4).Table 4 Correlation between serum levels of both Angiopoietin-2 an
Parameter Angiopoietin-2
r
CRP 0.773
Age (years) 0.285
Smoking index (Pack/year) 0.251
PaO2 0.963
PH 0.092
PCO2 0.260
SaO2% 0.426
Post bronchodilator FEV1 (L) 0.703
Post bronchodilator FEV1/FVC 0.514
Post bronchodilator FEF25–75 (L/S) 0.570
* Signiﬁcant.
** Highly signiﬁcant.These results were in agreement with Cho et al. (2010) who
indicated that Serum Ang-2 levels showed a signiﬁcant positive
correlation with levels of CRP, a marker of acute inﬂammation
in patients with COPD exacerbations [14].
Also, Nikolakopoulou et al. (2014) found that serum Ang-2
levels were positively correlated with CRP levels, supporting
the idea that inﬂammation exists in a mutually dependent asso-
ciation with angiogenesis. Serum Ang-2 may act as an inﬂam-
matory mediator, reﬂecting systemic inﬂammation more
speciﬁcally due to originating from the lung compared to CR
[15].d C-reactive protein and different parameters in COPD patients.
C-reactive protein
P value r P value
P0.001** – –
<0.05 0.058 < 0.05
<0.05 0.237 < 0.05
>0.001** 0.786 P0.001**
<0.05 0.004 <0.05
<0.05 0.189 <0.05
>0.001** 0.468 P0.001**
>0.001** 0.707 P0.001**
>0.001** 0.449 P0.001**
>0.001** 0.576 P0.001**
Biomarkers of acute exacerbations of chronic obstructive pulmonary diseases 841Serum levels of both Angiopoietin-2 and CRP were nega-
tively correlated with PaO2, SaO2%, and post bronchodilator
FEV1, FEV1/FVC, and FEF25–75% (Table 4).
De Torres et al., (2006) indicated that COPD patients with
low PaO2 values had higher serum Ang-2 levels than did
patients with high PaO2 values, they suggested that physicians
could use serum Ang-2 levels to assess oxygenation status and
predict outcomes in patients experiencing a COPD exacerba-
tion. It is widely accepted that COPD patients with hypoxemia
have lower survival rates [17].
Cho et al. (2010) indicated that hypoxia induced COPD
exacerbations promote the expression of Ang-2, resulting in
vascular leakage and inﬂammation of the pulmonary
microvasculature and airways. However, additional research
is needed to elucidate the precise role of Ang-2 in COPD exac-
erbations [14].
More over Oh (1999) indicated that in animal study
hypoxia resulted in the dysregulation of Ang-2 in bovine
microvascular endothelial cells [18].
Conclusion
From the present study we concluded that:
1- Serum Angiopoietin-2 and C-reactive protein levels are
signiﬁcantly elevated during acute exacerbations of
COPD.
2- Serum levels of Angiopoietin-2 and C-reactive protein
increased with increasing the severity of acute exacerba-
tions of COPD.
3- Serum Ang-2 levels is positively correlated with levels of
CRP, a marker of acute inﬂammation in patients with
COPD exacerbations.
4- Ang-2 levels are negatively correlated with PaO2 in
COPD exacerbation.
5- Ang-2 may be clinically useful as a biomarker of COPD
exacerbations to diagnose and asses its severity.
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